BLCO
Bausch + Lomb Corporation · Healthcare · Medical - Instruments & Supplies
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 46 | +1 | 24.68M | $408.72M | +5 | −4 |
| Q1 2026 | 45 | -1 | 23.90M | $380.01M | +5 | −6 |
| Q4 2025 | 46 | +1 | 23.58M | $402.66M | +2 | −1 |
| Q3 2025 | 13 | -2 | 16.68M | $251.34M | — | −2 |
| Q2 2025 | 12 | -2 | 14.01M | $182.32M | +1 | −3 |
| Q1 2025 | 12 | +1 | 9.66M | $140.02M | +2 | −1 |
| Q4 2024 | 11 | +3 | 8.82M | $159.20M | +3 | — |
| Q3 2024 | 7 | -1 | 7.17M | $138.23M | +1 | −2 |
| Q2 2024 | 8 | — | 5.22M | $75.80M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Icahn Capital ✦ | 3.50M | — | $50.82M | 0.5% | n/c | 1 | SEC ↗ |
| 2 | D. E. Shaw & Co. ✦ | 690.00K | — | $10.02M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 647.16K | — | $9.40M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Marshall Wace ✦ | 131.62K | — | $1.91M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 82.62K | — | $1.20M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 82.78K | — | $1.20M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | GAMCO Investors ✦ | 73.30K | — | $1.06M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 12.89K | — | $186,891 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 95 holders, 37.97M shares, $580.19M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 52.90K sh · $887,662
Director · 6.06K sh · $100,458
Director · 12.50K sh · $206,250
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology